Chronic VEGF Blockade Worsens Glomerular Injury in the Remnant Kidney Model

Carregando...
Imagem de Miniatura
Citações na Scopus
20
Tipo de produção
article
Data de publicação
2012
Título da Revista
ISSN da Revista
Título do Volume
Editora
PUBLIC LIBRARY SCIENCE
Citação
PLOS ONE, v.7, n.6, article ID e39580, 10p, 2012
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
VEGF inhibition can promote renal vascular and parenchymal injury, causing proteinuria, hypertension and thrombotic microangiopathy. The mechanisms underlying these side effects are unclear. We investigated the renal effects of the administration, during 45 days, of sunitinib (Su), a VEGF receptor inhibitor, to rats with 5/6 renal ablation (Nx). Adult male Munich-Wistar rats were distributed among groups S+V, sham-operated rats receiving vehicle only; S+Su, S rats given Su, 4 mg/kg/day; Nx+V, Nx rats receiving V; and Nx+Su, Nx rats receiving Su. Su caused no change in Group S. Seven and 45 days after renal ablation, renal cortical interstitium was expanded, in association with rarefaction of peritubular capillaries. Su did not worsen hypertension, proteinuria or interstitial expansion, nor did it affect capillary rarefaction, suggesting little angiogenic activity in this model. Nx animals exhibited glomerulosclerosis (GS), which was aggravated by Su. This effect could not be explained by podocyte damage, nor could it be ascribed to tuft hypertrophy or hyperplasia. GS may have derived from organization of capillary microthrombi, frequently observed in Group Nx+Su. Treatment with Su did not reduce the fractional glomerular endothelial area, suggesting functional rather than structural cell injury. Chronic VEGF inhibition has little effect on normal rats, but can affect glomerular endothelium when renal damage is already present.
Palavras-chave
Referências
  1. Ahmed A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013663
  2. ANDERSON S, 1985, J CLIN INVEST, V76, P612, DOI 10.1172/JCI112013
  3. Bollee G, 2009, NEPHROL DIAL TRANSPL, V24, P682, DOI 10.1093/ndt/gfn657
  4. BROWN LF, 1992, KIDNEY INT, V42, P1457, DOI 10.1038/ki.1992.441
  5. Costero O, 2010, NEPHROL DIAL TRANSPL, V25, P1001, DOI 10.1093/ndt/gfp666
  6. Eardley KS, 2008, KIDNEY INT, V74, P495, DOI 10.1038/ki.2008.183
  7. Eckardt Kai-Uwe, 2005, Kidney Int Suppl, pS46
  8. El Awad B, 2000, KIDNEY INT, V58, P43, DOI 10.1046/j.1523-1755.2000.00139.x
  9. Eremina V, 2010, SEMIN NEPHROL, V30, P582, DOI 10.1016/j.semnephrol.2010.09.006
  10. Eremina V, 2008, NEW ENGL J MED, V358, P1129, DOI 10.1056/NEJMoa0707330
  11. Eremina V, 2007, NEPHRON PHYSIOL, V106, P32, DOI 10.1159/000101798
  12. FLOEGE J, 1992, KIDNEY INT, V41, P297, DOI 10.1038/ki.1992.42
  13. Flyvbjerg A, 2002, AM J PHYSIOL-ENDOC M, V283, pE362, DOI 10.1152/ajpendo.00007.2002
  14. Foster RR, 2003, AM J PHYSIOL-RENAL, V284, pF1263, DOI 10.1152/ajprenal.00276.2002
  15. Fujihara CK, 1998, KIDNEY INT, V54, P1510, DOI 10.1046/j.1523-1755.1998.00138.x
  16. Fujihara CK, 2007, AM J PHYSIOL-RENAL, V292, pF1810, DOI 10.1152/ajprenal.00521.2006
  17. Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313
  18. Gkountouvas A, 2010, THYROID, V20, P597, DOI 10.1089/thy.2010.0028
  19. Guan FX, 2006, AM J PHYSIOL-RENAL, V291, pF422, DOI 10.1152/ajprenal.00448.2005
  20. HIROSE K, 1982, KIDNEY INT, V21, P689, DOI 10.1038/ki.1982.82
  21. ISAKA Y, 1993, J CLIN INVEST, V92, P2597, DOI 10.1172/JCI116874
  22. Izzedine H, 2007, AM J KIDNEY DIS, V50, P203, DOI 10.1053/j.ajkd.2007.04.025
  23. Izzedine H, 2007, CANCER CHEMOTH PHARM, V60, P357, DOI 10.1007/s00280-006-0376-5
  24. Izzedine H, 2010, EUR J CANCER, V46, P439, DOI 10.1016/j.ejca.2009.11.001
  25. JEPSEN FL, 1979, VIRCHOWS ARCH A, V383, P265, DOI 10.1007/BF00430245
  26. Kang DH, 2001, J AM SOC NEPHROL, V12, P1434
  27. Kappers MHW, 2009, J HYPERTENS, V27, P2297, DOI 10.1097/HJH.0b013e3283309b59
  28. Kappers MHW, 2010, HYPERTENSION, V56, P675, DOI 10.1161/HYPERTENSIONAHA.109.149690
  29. KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987
  30. Kelly DJ, 2003, NEPHROL DIAL TRANSPL, V18, P1286, DOI 10.1093/ndt/gfg176
  31. Kretzler M, 1998, Kidney Int Suppl, V67, pS159
  32. Kubo H, 2003, GENE DEV, V17, P322, DOI 10.1101/gad.1071203
  33. LAX DS, 1992, KIDNEY INT, V41, P1527, DOI 10.1038/ki.1992.222
  34. LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
  35. Manotham K, 2004, J AM SOC NEPHROL, V15, P1277, DOI 10.1097/01.ASN.0000125614.35046.10
  36. Mendel DB, 2003, CLIN CANCER RES, V9, P327
  37. Mimura I, 2010, NAT REV NEPHROL, V6, P667, DOI 10.1038/nrneph.2010.124
  38. Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044
  39. NAGATA M, 1992, KIDNEY INT, V42, P148, DOI 10.1038/ki.1992.272
  40. Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911
  41. PLOUET J, 1989, EMBO J, V8, P3801
  42. Rodriguez-Iturbe B, 2002, AM J PHYSIOL-RENAL, V282, pF191
  43. Schatteman GC, 2004, ANAT REC PART A, V276A, P13, DOI 10.1002/ar.a.10131
  44. Schrijvers BF, 2004, KIDNEY INT, V65, P2003, DOI 10.1111/j.1523-1755.2004.00621.x
  45. Schrijvers BF, 2005, NEPHRON EXP NEPHROL, V101, pE9, DOI 10.1159/000086034
  46. SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
  47. Sison K, 2010, J AM SOC NEPHROL, V21, P1691, DOI 10.1681/ASN.2010030295
  48. Spyridopoulos I, 1997, J MOL CELL CARDIOL, V29, P1321, DOI 10.1006/jmcc.1996.0365
  49. Tanaka T, 2010, CURR OPIN NEPHROL HY, V19, P43, DOI 10.1097/MNH.0b013e3283328eed
  50. WALLENSTEIN S, 1980, CIRC RES, V47, P1
  51. Wu QQ, 2006, AM J NEPHROL, V26, P97, DOI 10.1159/000092032
  52. Yang NS, 1998, NEPHROL DIAL TRANSPL, V13, P1967, DOI 10.1093/ndt/13.8.1967
  53. Yu DH, 2005, J AM SOC NEPHROL, V16, P1733, DOI 10.1681/ASN.2005020159